Safety, Pharmacokinetics, and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab (BGB-A317) in Participants With Advanced Solid Tumors
Clinical trial NCT05494762 · TERMINATED
Trial details
- NCT number
- NCT05494762
- Sponsor
- BeiGene
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2022-08-25
- Primary completion
- 2025-02-24
- Enrollment
- 55
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.